A mini review analyzes how pneumococcal conjugate vaccines reshape antimicrobial resistance through serotype replacement, clonal shifts, and vaccine design implications.
Key Takeaways
- We examine PCV-associated AMR dynamics through linked epidemiological
- We then explain why these effects are incomplete
- We argue that next-generation pneumococcal vaccines should be evaluated not only by immunogenicity and serotype coverage